John Markels - 16 Jul 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: Director
Issuer ticker: PCVX
Reported as of: 16 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jul 2026, 16:56:14 UTC
Prior SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: John Markels, by /s/ Peter N. Efremenko, Attorney-In-Fact

Key filing fact

John Markels filed Form 4 for Vaxcyte, Inc. (PCVX) on 16 Jul 2026.

Key facts

This page summarizes John Markels's Form 4 filing for Vaxcyte, Inc. (PCVX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jul 2026, 16:56.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001803424 Primary reporting owner

Markels John

Relationship: Director
Address: C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS
Signature: John Markels, by /s/ Peter N. Efremenko, Attorney-In-Fact
Signature date: 16 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +23,029
Change %
Price: $0.000000^*
Shares after: 23,029
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,029
Exercise price: $56.04
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Option shall vest over 36 months, 1/3 of which will vest on July 16, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.